By Business/Source
Currency:USD
2025/FY
Stock NameRevenueRatio
Developing, manufacturing and marketing generic and biosimilar medicines11.16B100.00%
By Country/Region
Currency:USD
2025/FY
Stock NameRevenueRatio
Other7.34B65.81%
United States1.83B16.42%
Germany1.42B12.71%
Switzerland494M4.43%
Other revenues71M0.64%